Isabel Kalofonos's most recent trade in Crinetics Pharmaceuticals Inc was a trade of 2,500 Common Stock done at an average price of $40.6 . Disclosure was reported to the exchange on Jan. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.59 per share. | 05 Jan 2026 | 2,500 | 3,334 (0%) | 0% | 40.6 | 101,475 | Common Stock |
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 05 Jan 2026 | 2,500 | 834 (0%) | 0% | 55 | 137,500 | Common Stock |
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 2,500 | 97,500 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Immunogen Inc | Isabel Kalofonos | SVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 284,250 | 284,250 | - | - | Stock Option (Right to Buy) | |
| Immunogen Inc | Isabel Kalofonos | SVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 47,375 | 47,375 | - | - | Restricted Stock Unit |